This month, the Sabin Vaccine Institute will begin a Phase-1 clinical trial in Washington, DC to further investigate the Na-GST-1 human hookworm vaccine candidate.

In an op-ed published Friday, Sabin president Peter Hotez, M.D., Ph.D., and his Baylor College of Medicine colleague, William Brinkley, Ph.D., applaud the dramatic gains Texas institutions have made to become leaders among the global scientific community. They cite the routinely high ranking of public and private Texas universities as well as a voter approved amendment to start the Cancer Prevention and Research Institute of Texas (CPRIT).

Financing research and development (R&D) for neglected tropical disease (NTDs) is a big challenge. The problem? Market failure.

This article, written by Dr. Peter Hotez, president of Sabin Vaccine Institute and dean of the National School of Tropical Medicine at Baylor College of Medicine, originally appeared in TAMEST (The Academy of Medicine, Engineering and Science of Texas) e-news.

Pages